Search for content, post, videos

Life Science Director appointed at MAX IV Laboratory

Tomas Lundqvist has a long and prosperous career within structural biology and drug discovery and is from January 1st 2014 Life Science Director at MAX IV Laboratory.

”I am very happy and extremely proud for being given this chance to be part of the great team at MAX IV Laboratory,” says Tomas Lundqvist. ”When the opportunity revealed itself there was no hesitation on my part. I have followed the laboratory over the years and I am very impressed with the results and the plans for the future. Being part of the future development and making use of my experience, both as a scientist and from within the life science industry, in making this unique and world leading facility even better is a great opportunity and I am eager to take on the work.”

Tomas Lundqvist got his Ph.D. in molecular and structural biology at the Department of Molecular Biology at SLU in Uppsala, Sweden. After two post-doc periods, DuPont CR&D (Wilmington, USA) and MRC Laboratory of Molecular Biology (Cambridge, UK) he returned to Sweden 1992 to set up the protein crystallography group at Pharmacia in Stockholm. He joined AstraZeneca in December 1996 to build a similar function at the research site in Mölndal. Since 2008 he has been Director in Discovery Sciences at AstraZeneca, a global function, supporting drug discovery projects particularly in the early phase. Tomas has over the years served as an industrial representative in various bodies related to the use and the strategic development of synchrotrons and other large-scale facilities; most lately as a member of the SAC for the European Spallation Source (ESS).

”Recruiting the expertise and experience that Tomas Lundqvist has is of crucial importance,” says Christoph Quitmann, director of MAX IV Laboratory. ”Tomas is a person combining profound experience with a real vision for the future. He will be a key person enabling us to become a laboratory serving all of natural science and life science in particular. I am very happy to welcome him to Lund and to the MAX IV Laboratory team.”